Amy Abernethy
Showing 1–2 of 2 transcripts.
- a16z44 min
Food, Drugs, and Tech: 100 years of Public Health
Established in 1906 to address public health crises, the FDA is currently transitioning its 20% GDP-regulated portfolio from legacy physical archives to a fully digital, data-informed infrastructure that leverages machine learning for food safety and pathogen tracking. While modernizing clinical trial frameworks through the 21st Century Cures Act to accommodate gene therapies and real-world evidence, the agency balances risk aversion with the urgent need to approve life-saving innovations like cell-cultured foods and AI-driven medical devices. This evolution positions the FDA to shift from reactive disease treatment to preventative longitudinal care, utilizing synthetic data and dynamic regulatory paradigms to manage emerging biological technologies over the next century.
- a16z36 min
a16z Podcast | Connecting Hearts, Bodies, and Networks to Cure Cancer
Amy Abernethy, Christina Lopes, Jorge Conde, Sonal
Amy Abernethy has been selected as the new Principal Deputy Commissioner of the FDA, where she aims to advance personalized medicine and accelerate evidence generation following her tenure at Flatiron Health. Her appointment aligns with the growing adoption of One Health strategies, a platform co-founded by Cristina Lopez that leverages spontaneous canine cancer data to validate human therapies. By treating dogs as natural clinical models with fully functional immune systems, this initiative promises to save costs in drug development and improve outcomes for both veterinary and human patients through shared real-world evidence.